Supporting Materials
Ampicillin sodium, AIM-terrific broth base including trace elements, Tris base Ultra-Pure, EDTA disodium and DTT dithiothreitol were obtained from ForMedium™ (UK). Calcium chloride (anhydrous) and urea (carbamide) were obtained from Melford (UK). Imidazole, Glycerol, N, N, N', sodium chloride,  agarose, ribonuclease A (from bovine pancreas) and Bromophenol Blue sodium salt were obtained from Sigma Life Science (UK). cOmplete™ ULTRA Tablets, glass vials Protease Inhibitor Cocktail and cOmplete™ His-Tag Purification Resin were from Roche (Germany).
Sodium hydrochloride and methanol were obtained from Fisher Scientific (UK). Acetic acid ≥99.0% (T) and skimmed milk powder were obtained from Fluka Analytical (Switzerland).
Triton® X-100, sodium carbonate, ammonium persulfate and Bovine Serum Albumin lyophilized powder, ≥96% (agarose gel electrophoresis) were obtained from Sigma-Aldrich (Germany). Citric acid monohydrate and Brilliant Blue R were obtained from Sigma (UK). 
Supporting Methods

Cell culture
A panel of cell lines, of varied degree of HER2 expression, was used in this study. The BT-20 human breast carcinoma (BT-20; ATCC, HTB-19) was cultured in MEM media supplemented with 15% fetal bovine serum (FBS), 50 U/ml penicillin, 50 µg/ml streptomycin, 1% L-glutamine, at 37 °C in 5% CO 2 . The IGROV-1 human ovarian adenocarcinoma (IGROV-1; RRID, CVCL_1304) and SKOV-3 human ovary adenocarcinoma (SKOV-3;
ATCC, HTB-77) were cultured in DMEM media supplemented with 10% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 1% L-glutamine, at 37 °C in 5% CO 2 . The HeLa human cervix adenocarcinoma (HeLa; ATCC, CCL-2) were cultured in DMEM media supplemented with 10% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin, 1% L-glutamine, at 37 °C in 5% CO 2 . All cells were routinely grown in 75 cm 2 canted-neck tissue culture flasks and passaged twice a week using Trypsin/EDTA at 80% confluency. 
Determination of HER2 receptors expression levels in cancer cell lines
Supporting Results
Characterisation of cancer cells for HER2 expression
HER2 expression levels in 9 cancer cell lines, including MDA-MB-468, MDA-MB-231, IGROV-1, HeLa, BT-20, SKOV-3, MDA-MB-435-MLE, SKBR-3 and BT-474 cells, were assessed using flow cytometry. Expression levels were assessed by measuring the median fluorescent intensity (MFI) using FL-2 detector. Cell lines were stained with PE mouse antihuman HER2/neu primary antibody. κ isotype was used as a negative control.
As shown in Figure 
Fluorescence labelling of HBc particles
All HBc particles were fluorescently labelled with Alexa Fluor™ 488 dye. Fluorescence was measured with excitation at 485 nm and emission at 520 nm, using BMG FLUOstar Omega fluorometer. As shown in Figure S2 , HBc particles showed higher fluorescence intensity than
ΔHBc and Z HER2 -ΔHBc particles ( Figure S2 ).
In vivo monitoring of highly-expressing HER2 (HER2 (+++)) xenograft tumour models by bioluminescence imaging
In order to study the biodistribution of HBc particles in an in vivo model, two tumour mice models were prepared; intraperitoneal and mammary fat pad tumour models. NSG mice were (Figure S7C, D) .
In the intraperitoneal tumour mouse model, accumulation of 99m Tc-ΔHBc was observed in kidneys > liver > spleen followed by lungs at %ID/g values of 13.90 ± 1.08, 9.88 ± 1.24, 9.27 ± 0.57 and 3.41 ± 0.40% at 24 h post-injection ( Figure S8A, black bars) . A similar trend in organ accumulation profile was observed for 99m Tc-Z HER2 -ΔHBc ( Figure S8A, grey bars) .
The mammary fat pad tumour mouse model exhibited comparable organ biodistribution profiles to those observed in intraperitoneal tumour mouse model ( Figure S8B) . A statitiscally significant higher lung (*p < 0.05) and lower kidney (**p < 0.01) uptakes were observed for 99m Tc-Z HER2 -ΔHBc compared to 99m Tc-ΔHBc.
Tumour uptake of systemically-administered HBc particles exhibited low uptake with ~ 0.5% and ~0.2% achieved in the intraperitoneal and mammary fat pad tumour model, respectively, with no significant differences observed between 99m Tc-ΔHBc and 99m Tc-Z HER2 -ΔHBc ( Figure S8 ).
Excretion profiles of locally-administered HBc particles by gamma counting
In the intraperitoneal tumour-bearing mice model, approximately ~4-10% and ~0.2-2.0 %ID was eliminated into urine and faeces after 24 h for both particles with no significant differences between the type of particles (p > 0.05) ( Figure S9A ). In contrast, in the mammary fat pad tumour-bearing mice model, higher radioactivity was observed in urine for both HBc particles after 24 h (~17-22%) than found with the intraperitoneal model.
Approximately ~20-30% and ~1.6-1.7 %ID was eliminated into urine and faeces after 24 h for both particles (p > 0.05) ( Figure S9B ). 
